COX-2 Inhibition in Allergic Asthma

Exclusion Criteria

• •Known or suspected hypersensitivity to coxibs
• •Any significant respiratory disease other than asthma
• •Respiratory tract infection within 4 weeks before inclusion.
• •Current or former smoker within the last year and a smoking history of \>4 packyears
• •Pregnancy/breastfeeding
• •Use of:
• •* inhaled glucocorticosteroid treatment or use of oral corticosteroids for the last 8 weeks prior to inclusion or during the study.
• •* inhaled long-acting or oral beta2-agonists, anticholinergic bronchodilators, cromones, antihistamines, theophyllines and antileukotrienes within 2 weeks of screening or during the study.
• •* paracetamol, NSAIDs or any other antiinflammatory drugs the last 2 weeks prior to inclusion or during the study.
• •* need of any other regular drug treatment that may interfere with the study outcomes.
• •BMI \>30 kg/m2.
• •Use of any beta-blocking agent
• •Any non-asthma-related, clinically significant abnormal finding in physical and/or vital signs, and/or in hematology or blood chemistry tests at visit 1, which in the opinion of the investigator, may put the patient at risk because of participation in the study.